Drug Trial Radar · NCT01919697
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)
Last checked: Nov 20, 2026Latest source record: Jul 2, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,370
Actual
Start
Aug 2013
Primary completion
Jan 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- Bausch Health Americas, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Aug 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 81 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, 52-week safety and tolerability study of plecanatide in patients with Chronic Idiopathic Constipation (CIC).
Conditions
- Chronic Idiopathic Constipation
Interventions
PlecanatideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE)Time frame: From first dose up to 72 weeks
- Number of Patients With at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Discontinuation of PlecanatideTime frame: From first dose up to 72 weeks
- Summary of Vital Signs at >Day 364 - Blood Pressure (Systolic and Diastolic; mmHg)Time frame: From first dose up to 72 weeks
- Summary of Vital Signs at >Day 364 - Heart Rate (Beats Per Minute)Time frame: From first dose up to 72 weeks
- Summary of Vital Signs at >Day 364 - Body Temperature (°C)Time frame: From first dose up to 72 weeks
- Summary of Vital Signs at >Day 364 - Respiration Rate (Breaths Per Minute)Time frame: From first dose up to 72 weeks
- Summary of ECG Results Shift From Baseline at > Day 364Time frame: From first dose up to 72 weeks
- Summary of Treatment-Emergent Laboratory Abnormalities With At Least a 1-grade Shift From BaselineTime frame: From first dose up to 72 weeks
Locations
220 sites in 2 countries. Site status is shown where the registry gives one.
Synergy Research Site
Birmingham, Alabama
Synergy Research Site
Dothan, Alabama
Synergy Research Site
Gulf Shores, Alabama
Synergy Research Site
Huntsville, Alabama
Synergy Research Site
Chandler, Arizona
Synergy Research Site
Phoenix, Arizona
Synergy Research Site
Tempe, Arizona
Synergy Research Site
Tucson, Arizona
Synergy Research Site
Tucson, Arizona
Synergy Research Site
Tucson, Arizona
Synergy Research Site
Little Rock, Arkansas
Synergy Research Site
North Little Rock, Arkansas
Synergy Research Site
Anaheim, California
Synergy Research Site
Anaheim, California
Synergy Research Site
Artesia, California
Synergy Research Site
Carlsbad, California
Synergy Research Site
Cerritos, California
Synergy Research Site
Chula Vista, California
Synergy Research Site
Corona, California
Synergy Research Site
Encinitas, California
Synergy Research Site
Fountain Valley, California
Synergy Research Site
Fresno, California
Synergy Research Site
Hawaiian Gardens, California
Synergy Research Site
La Mirada, California
Synergy Research Site
Laguna Hills, California
Synergy Research Site
Lancaster, California
Synergy Research Site
Long Beach, California
Synergy Research Site
Los Angeles, California
Synergy Research Site
Los Angeles, California
Synergy Research Site
Mission Hills, California
Synergy Research Site
North Hollywood, California
Synergy Research Site
Orange, California
Synergy Research Site
Pasadena, California
Synergy Research Site
Sacramento, California
Synergy Research Site
San Diego, California
Synergy Research Site
San Diego, California
Synergy Research Site
San Diego, California
Synergy Research Site
Thousand Oaks, California
Synergy Research Site
Colorado Springs, Colorado
Synergy Research Site
Colorado Springs, Colorado
Showing 40 of 220 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.